Evidence map›Paper›PMID 41937692›Full record

ArticleHLA2026

HLA Class II Protein Expression Regulation Is Strongly Linked to Cis-Acting SNPs.

Nicolas Vince, Veron Ramsuran, Mathias Viard, Jeremy Martinson, Steven Wolinsky, Shehnaz Hussain, Eric C Seaberg, Todd T Brown, Niamh Spence, Chloe L Thio and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nicolas VinceBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-3767-6210
Veron RamsuranBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, Maryland, USA.
Mathias ViardBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, Maryland, USA.
Jeremy MartinsonUniversity of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.
Steven WolinskyDivision of Infectious Diseases, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois, USA.
Shehnaz HussainDivision of Epidemiology, University of California Davis, School of Medicine, Davis, California, USA.
Eric C SeabergBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Todd T BrownBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Niamh SpenceBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, Maryland, USA.
Chloe L ThioJohns Hopkins University, School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-8851-8319
James J GoedertNational Cancer Institute, Washington, DC, USA.
W Keith HootsDivision of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gregory D KirkDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, Maryland, USA.

Funding

University of Pittsburgh MWCCS Clinical Research SiteU01HL146208 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Bernard Jonas C Macatangay, CHARLES R RINALDO · 2019 to 2026
$32.2M
NHLBI NIH HHS U01 HL146208
6 · The paper itself

Abstract

Allele-specific variability in HLA class I gene expression levels has been associated with many diseases. Although expression variation at the allelic level has not been well-characterised for the HLA class II genes, differential expression of these genes, as marked by single nucleotide polymorphisms (SNPs), has been implicated in the outcome of several diseases. Here, we measured cell surface expression levels of distinct HLA-DR, HLA-DQ and HLA-DP allotypes in 175 healthy European American donors using locus-specific antibodies. We identified allotype-specific variation in the intrinsic cell surface expression levels. To further characterise genetic associations with differential protein expression levels of the HLA class II molecules, we performed a genome-wide association study (GWAS). This showed that surface expression levels of HLA-DR, HLA-DQ and HLA-DP associated most significantly with rs28383323 (p = 3.9 × 10

Indexed as

Gene Expression RegulationHLA-DP AntigensHLA-DQ AntigensHLA-DR AntigensPolymorphism, Single NucleotideAllelesGenome-Wide Association StudyHumansHLA-DP AntigensHLA-DQ AntigensHLA-DR Antigens

Identifiers

PMID41937692
PMCPMC13051461

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.